drugset / Trial / NCT03125876
A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CT053PTSA in Relapsed/refractory AML patients with FLT3 gene mutation.
Timeline
- Start
- 2017-11-13
- Primary completion
- 2019-08-19
- Completion
- 2019-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT053PTSA | Unknown | 60 mg | Oral |
| Subject | CT053PTSA | Unknown | 80 mg | Oral |
| Subject | CT053PTSA | Unknown | 100 mg | Oral |